Vertex Pharmaceuticals Receives Consensus Recommendation of “Hold” from Brokerages (NASDAQ:VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) has received an average rating of “Hold” from the seventeen ratings firms that are covering the company, American Banking News reports. Eight equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $102.82.
In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,200 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $93.31, for a total value of $485,212.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, July 31st. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Finally, analysts at Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th.
Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 93.57 on Tuesday. Vertex Pharmaceuticals has a one year low of $58.06 and a one year high of $99.74. The stock has a 50-day moving average of $92.1 and a 200-day moving average of $79.38. The company’s market cap is $22.277 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Tuesday, July 29th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was down 55.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.90 EPS for the current fiscal year.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.